Related Experiment Videos
Neonatal hepatobiliary disorders
1Department of Pediatrics, University of Florida College of Medicine, Shands Hospital, Gainesville, USA.
Insights
Neonatal hepatobiliary disorders are better understood with advances in genetics and immunology. Early recognition of cholestatic issues is crucial for timely intervention and improved infant outcomes.
Area of Science:
- Neonatology
- Hepatology
- Molecular Genetics
- Virology
- Immunology
Background:
- Neonatal hepatobiliary disorders necessitate prompt recognition and intervention.
- Advances in molecular genetics, virology, and immunology enhance understanding of these conditions.
- Hepatocellular and ductal cholestasis in newborns require specialized medical attention.
Purpose of the Study:
- To review recent developments in neonatal hepatobiliary disorders.
- To discuss the potential of gene therapy for neonatal metabolic disorders.
- To update knowledge on perinatal infections and their impact.
Main Methods:
- Literature review focusing on molecular genetics, virology, and immunology.
- Analysis of new concepts in neonatal hepatitis and biliary atresia.
- Examination of predictors for outcomes in surgical interventions.
Main Results:
- Improved understanding of neonatal cholestatic disorders.
- Insights into gene therapy applications for metabolic conditions.
- Updated information on viral infections affecting newborns.
- Review of prognostic factors for Kasai portoenterostomy and liver transplantation.
Conclusions:
- Advances in science are improving the diagnosis and understanding of neonatal liver diseases.
- Early detection and intervention remain critical for managing these conditions.
- Further research into gene therapy and predictive markers can optimize patient outcomes.
Abstract:
Neonatal hepatobiliary disorders are now better understood due primarily to new discoveries in molecular genetics, virology, and immunology. Because they are almost always pathologic and require early intervention, the neonatologist must recognize infants with these hepatocellular and ductal cholestatic problems occurring in the first few weeks of life. This article focuses mainly on new developments regarding neonatal metabolic disorders and their potential for gene therapy; perinatal infections, especially those caused by hepatitis B virus, hepatitis C virus, and human immunodeficiency virus; and recent concepts of neonatal hepatitis and biliary atresia, including a review of predictors that influence outcome for infants undergoing Kasai portoenterostomy and liver transplantation.